Want to see HK:0874 full AI Analyst Report?
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) Stock Price & Analysis
0874 Stock Chart & Stats
- Day’s Range
- HKD 12.78 - HKD 13.07
- 52-Week Range
- HKD 12.52 - HKD 20.40
- Previous Close
- HKD 12.86
- Volume
- N/A
- Average Volume (3M)
- 980.92K
- Market Cap
- HKD 35.32B
- Enterprise Value
- HKD 37.68B
- Total Cash (Recent Filing)
- HKD 11.90B
- Total Debt (Recent Filing)
- HKD 23.24B
- Price to Earnings (P/E)
- 15.0
- Beta
- 0.51
- Next Earnings
- Mar 12, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Sep 03, 2026
- Dividend Yield
- 6.62%
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Strong 28% TTM revenue growth indicates that the company is expanding its sales base across pharmaceutical and healthcare activities. If sustained, this growth can improve operating scale, support reinvestment in products and distribution, and reinforce its position across hospital and consumer channels.
Diversified Business Model
The combination of pharmaceutical manufacturing and distribution gives Baiyunshan multiple routes to generate revenue, while its TCM, western medicine, prescription, OTC and wellness portfolio reduces reliance on one product category. This breadth supports channel diversification and cross-selling.
Manageable Balance Sheet
Moderate leverage and a growing equity base provide a workable financial foundation for a large pharmaceutical and distribution group. This balance-sheet position should preserve some capacity to support operations and investment, even though returns have recently softened.
Bears Say
Margin Compression
The decline in net margin shows that revenue growth is not translating proportionally into earnings. Continued compression in net, EBITDA and operating margins could limit internal funding, reduce the benefit of scale, and make future profitability more dependent on product mix and cost control.
Inconsistent Cash Conversion
Volatile free cash flow and the negative 2025 result indicate that accounting earnings have not converted consistently into cash. This can constrain reinvestment, dividends or debt reduction and suggests that working-capital movements may continue to make financial performance less predictable.
Rising Leverage And Lower Returns
The combination of higher leverage and declining return on equity points to weaker capital efficiency than in earlier years. More debt increases financial commitments, while lower ROE suggests that the enlarged equity and asset base is currently generating less profit for shareholders.
Guangzhou Baiyunshan Pharmaceutical Holdings Company News
0874 FAQ
What was Guangzhou Baiyunshan Pharmaceutical Holdings Company’s price range in the past 12 months?
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company’s market cap?
When is Guangzhou Baiyunshan Pharmaceutical Holdings Company’s upcoming earnings report date?
How were Guangzhou Baiyunshan Pharmaceutical Holdings Company’s earnings last quarter?
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company overvalued?
Does Guangzhou Baiyunshan Pharmaceutical Holdings Company pay dividends?
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company’s EPS estimate?
How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company have?
What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company?
What is the TipRanks Smart Score and how is it calculated?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials and their intermediates, alongside natural and biological remedies, serving both the Chinese domestic market and international clientele. The company's operations are strategically divided into four primary segments: Great Southern TCM, Great Commerce, Great Health, and Others. Beyond its manufacturing activities, GBPHCL is actively involved in the import, export, wholesale, and retail of both Western and Chinese medicines, as well as medical equipment. The company also develops, manufactures, and sells various consumer goods including beverages, food products, health supplements, pre-packaged foods, dairy items, and diverse pharmaceutical forms such as tablets, capsules, lozenges, and injections, in addition to traditional items like tortoise herb jelly. Furthermore, GBPHCL makes strategic investments in the broader health industry, covering areas like medical services, health management, wellness initiatives, and elderly care. It also provides commercial and advertising solutions. As of December 31, 2021, the company maintained a substantial retail presence, managing 154 chain pharmacies operating under brands like Cai Zhi Lin, Jian Min, GPC Prescription Pharmacy, and Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd, supplemented by an additional 22 independent retail stores. Established in 1997, the company originally operated as Guangzhou Pharmaceutical Company Limited before adopting its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. Its headquarters are situated in Guangzhou, China.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Yuan Cheng
- Employees
- 27,057
- Website
- www.gybys.com.cn
- Address
- 45 Sha Mian North Street, Guangzhou, GD, 510130, CN
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) Earnings & Revenues
0874 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 4 | 0 | 8 |
